The Journal of Korean Medicine (대한한의학회지)

The Society of Korean Medicine (대한한의학회)
권호 표지
DOI QR코드

DOI QR Code

A Case Report of Improvement of Docetaxel-induced Fluid Retention in a Patient with Advanced Gastric Cancer using Herbal Decoction, Modified Bangkihwangki-tang

  • Choi, Seong-Heon (Cancer center of Traditional Korean Medicine, Kyung Hee University hospital at Gangdong) ;
  • Lee, Jee Young (Cancer center of Traditional Korean Medicine, Kyung Hee University hospital at Gangdong) ;
  • Lee, Sung-Un (Graduate school of Clinical Korean Medicine, Kyung Hee University) ;
  • Lee, Soo-Min (Graduate school of Clinical Korean Medicine, Kyung Hee University) ;
  • Park, Sora (Graduate school of Clinical Korean Medicine, Kyung Hee University) ;
  • Jung, Yee-Hong (Graduate school of Clinical Korean Medicine, Kyung Hee University)
  • Received : 2014.11.24
  • Accepted : 2014.12.19
  • Published : 2014.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: A 54-year-old advanced gastric cancer patient developed severe fluid retention after docetaxel chemotherapy, at cumulative dose of $930mg/m^2$, with no improvement using diuretics or prophylactic glucocorticoids. Consequently, he changed chemotherapy regimen from docetaxel to paclitaxel. After he treated with herbal decoction Bangkihwangki-tang (BHT), which is widely used to treat several symptoms including edema in traditional Korean medicine, docetaxel-induced fluid retention (DIFR) was significantly improved along with associated symptoms, such as peripheral edema, pleural and pericardial effusion, pain, scleroderma, and hypoesthesia. As the symptoms were relieved, his performance status and ambulatory ability were improved. During herbal treatment, he continued chemotherapy without any problems and didn't show any adverse events related to herbal medicine. Although there is possibility of natural improvement progress after withdrawal of docetaxel, he showed shorter recovery period and significant improvement despite of severity of initial symptoms.

Keywords

References

  1. Amathieu R, Tual L, Fessenmeyer C, Dhonneur G. Docetaxel-induced acute pulmonary capillary -leak syndrome mimicking cardiogenic oedema. Ann Fr Anesth Reanim. 2007;26(2):180. https://doi.org/10.1016/j.annfar.2006.10.024
  2. Ohnishi N, Nagasawa K, Yokoyama T. The verification of regulatory effects of Kampo formulations on body fluid using model mice. Journal of Traditional Medicines. 2000;17(3):131-136.
  3. Kim CU, Ryu DG, Lee EJ. The effects of Bangkihwangki-tang on renal functions in rabbit. The Korean Journal of Oriental Medical Prescription. 1990;1(1):183-195.
  4. Gautam M, Atsushi I, Tatsuya S, Saeko Y, Hirohiko M, Takeshi T, et al. The Traditional Japanese Medicine (Kampo) Boiogito has a Dual Benefit in Cardiorenal Syndrome: A Pilot Observational Study. Shinshu Med J. 2014;62:89-97.
  5. Park JH, Bose S, Lim CY, Kim HJ. Impact of GNB3, ADRB3, UCP2, and PPAR$\gamma$-Pro12Ala polymorphisms on Boiogito response in obese subjects : A randomized, double-blind, placebo -controlled trial. Journal of Society of Korean Medicine for Obesity Research. 2012;12(2):28-43.
  6. Majima T, Inoue M, Kasahara Y, Onodera T, Takahashi D, Minami A. Effect of the Japanese herbal medicine, Boiogito, on the osteoarthritis of the knee with joint effusion. Sports Med Arthrosc Rehabil Ther Technol. 2012;4(3).
  7. Chen G, Liu H, Cheng F. Fangjihuangqi tang improved lower urinary tract dysfunction in benign prostatic hyperplasia rats model. J Tradit Chin Med. 2013;33(3):349-54. https://doi.org/10.1016/S0254-6272(13)60177-6
  8. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol. 1995;13(10):2643. https://doi.org/10.1200/JCO.1995.13.10.2643
  9. Burris HA. Optimal use of docetaxel (Taxotere): maximizing its potential. Anticancer Drugs. 1996;7 Suppl 2:25-28. https://doi.org/10.1097/00001813-199608002-00007
  10. Chan S, Friedrichs K, Noel D, Pinter T, Van BS, Vorobiof D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1999;17(8):2341-54. https://doi.org/10.1200/JCO.1999.17.8.2341
  11. Behar A, Pujade-Lauraine E, Maurel A, Brun MD, Chauvin FF, Feuilhade de CF, et al. The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication. Br J Clin Pharmacol. 1997;43(6):653-8. https://doi.org/10.1046/j.1365-2125.1997.00613.x
  12. Semb KA, Aamdal S, Oian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol. 1998;16(10):3426-32. https://doi.org/10.1200/JCO.1998.16.10.3426